Accordingly, OTX was selected for GBM synergistic treatment for three main reasons: 1) it is able to turn “cold” immunosuppressive GBM into T cell inflamed “hot” tumor via inhibiting the PD‐1/PD‐L1 pathway, leading to powerful immunotherapy; 2) OTX can inhibit the DNA repairment via acting as an inhibitor of bromodomain protein 4 (BRD4), thus reducing development of TMZ drug resistance; 3) OTX itself also has innate antitumor activity. Here, CD274 is linked to neoplasm.